Skip to main content

Table 3 Risk prediction of change in UAE in response to ARB therapy

From: Serum metabolites predict response to angiotensin II receptor blockers in patients with diabetes mellitus

  R2 p value* Discrimination of >30 % decrease in UAE
ROC 95 % CI p value* IDI 95 % CI p value*
Discovery cohort
 Clinical parametersa 0.10 Ref. 0.72 0.57 0.87 Ref.   Ref.  
  +Serum metabolites classifier 0.70 <0.001 0.95 0.89 1.00 0.001 0.50 0.36 0.63 <0.001
  +Subset of 7 metabolitesb 0.50 <0.001 0.90 0.81 0.99 0.012 0.33 0.19 0.47 <0.001
Validation Cohort
 Clinical parametersa 0.20 Ref. 0.74 0.59 0.89 Ref.   Ref.  
  +Serum metabolites classifier 0.53 <0.001 0.89 0.79 0.99 0.063 0.30 0.15 0.46 <0.001
  +Subset of 7 metabolitesb 0.35 0.002 0.78 0.64 0.92 0.460 0.19 0.09 0.47 0.055
  1. * Comparing clinical parameters + metabolites to only clinical parameters
  2. aBaseline Age, Sex, SBP, HbA1c, GFR, UAE
  3. bMetabolites assigned to both drug interference:direct disease phenotype and disease progression processes (seven metabolites: ADMA, citrulline, lysoPC a C16:0, lysoPC A C16:1, PC aa C36:0, PC aa C42:2, tryptophan)